Research on AHK-Cu specifically has examined its potential to support the anagen (growth) phase of the hair cycle, promote dermal papilla cell proliferation, and stimulate VEGF (vascular endothelial growth factor), which supports blood flow to follicles
The FDA's classification indicates the need for more rigorous investigation, impacting the availability and distribution of BPC 157
Understanding the methylation terrain first is what makes any cadence a deliberate choice
Phase 3 trials were not initiated, and the compound does not hold any approved fat loss indication
"Mechanisms" people cite (and what they don't prove) You'll often see references to growth factors and vascular signaling (like pathways associated with tissue repair)
continued improvement expected Month 6-12 Full results achieved with consistent use Cheat Sheets Featuring AHK-Cu See how AHK-Cu fits into a broader research stack with these free downloadable cheat sheets
